Literature DB >> 1410129

Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics.

C Mondadori1, T Ducret, A Häusler.   

Abstract

Oral pretreatment of mice with aldosterone or corticosterone blocked the memory-enhancing effects of piracetam, pramiracetam, aniracetam and oxiracetam in a dose-related manner, without, however, impairing the animals' learning performance. The improvement of memory induced by physostigmine, arecoline, and tacrine (THA) was similarly inhibited. The fact that elevated steroid levels suppress the memory-enhancing effects of entirely different substances could indicate that these substances have a common site of action. In the light of new observations showing increased cortisol concentrations in Alzheimer patients, this steroid dependency of the effects of memory enhancers might explain why only a limited number of these patients respond to therapy with nootropics or cholinomimetics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1410129     DOI: 10.1007/bf02245278

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Tetrahydroaminoacridine and lecithin for Alzheimer's disease.

Authors: 
Journal:  N Engl J Med       Date:  1990-09-27       Impact factor: 91.245

3.  Aldosterone receptors are involved in the mediation of the memory-enhancing effects of piracetam.

Authors:  C Mondadori; A Häusler
Journal:  Brain Res       Date:  1990-08-06       Impact factor: 3.252

4.  The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task.

Authors:  C L Murray; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Experiments with UCB 6215, a drug which enhances acquisition in rats: its effects compared with those of metamphetamine.

Authors:  O L Wolthuis
Journal:  Eur J Pharmacol       Date:  1971 Nov-Dec       Impact factor: 4.432

6.  Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal.

Authors:  A Häusler; G Monnet; C Borer; A S Bhatnagar
Journal:  J Steroid Biochem       Date:  1989       Impact factor: 4.292

7.  Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent.

Authors:  L B Sourander; R Portin; P Mölsä; A Lahdes; U K Rinne
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Experimental behavioral studies with oxiracetam on different types of chronic cerebral impairment.

Authors:  S Banfi; L Dorigotti
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

9.  Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.

Authors:  R Cumin; E F Bandle; E Gamzu; W E Haefely
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

10.  Dementia of the Alzheimer type and hypothalamus-pituitary-adrenocortical axis: changes in cerebrospinal fluid corticotropin releasing factor and plasma cortisol levels.

Authors:  E Martignoni; F Petraglia; A Costa; G Bono; A R Genazzani; G Nappi
Journal:  Acta Neurol Scand       Date:  1990-05       Impact factor: 3.209

View more
  7 in total

1.  Pretreatment with aldosterone or corticosterone blocks the memory-enhancing effects of nimodipine, captopril, CGP 37,849, and strychnine in mice.

Authors:  C Mondadori; C Gentsch; B Hengerer; T Ducret; J Borkowski; A Racine; R Lederer; A Haeusler
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  The memory-facilitating effects of the competitive NMDA-receptor antagonist CGP 37849 are steroid-sensitive, whereas its memory-impairing effects are not.

Authors:  C Mondadori; J Borkowski; C Gentsch
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

3.  Delayed emergence of effects of memory-enhancing drugs: implications for the dynamics of long-term memory.

Authors:  C Mondadori; B Hengerer; T Ducret; J Borkowski
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

4.  THE RELATIONSHIP BETWEEN ACUTE GLUCOCORTICOID LEVELS AND HIPPOCAMPAL FUNCTION DEPENDS UPON TASK AVERSIVENESS AND MEMORY PROCESSING STAGE.

Authors:  Cheryl D Conrad
Journal:  Nonlinearity Biol Toxicol Med       Date:  2005

5.  Reversal of cycloheximide-induced memory disruption by AIT-082 (Neotrofin) is modulated by, but not dependent on, adrenal hormones.

Authors:  Rongzi Yan; Quang Nguyen; James Gonzaga; Mai Johnson; Ronald F Ritzmann; Eve M Taylor
Journal:  Psychopharmacology (Berl)       Date:  2003-02-26       Impact factor: 4.530

Review 6.  Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.

Authors:  C R Lee; P Benfield
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

7.  Dexamethasone target sites in the central nervous system and their potential relevance to mental illness.

Authors:  M K Birmingham; M Sar; W E Stumpf
Journal:  Cell Mol Neurobiol       Date:  1993-08       Impact factor: 5.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.